A5030864476- Viral Infections and Outbreaks Research
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Rabies epidemiology and control
- Biochemical Acid Research Studies
- Mosquito-borne diseases and control
- Pharmacological Effects of Natural Compounds
- Influenza Virus Research Studies
- Lysosomal Storage Disorders Research
- Respiratory viral infections research
- Venomous Animal Envenomation and Studies
- Viral Infections and Vectors
- Poxvirus research and outbreaks
Mirna Therapeutics (United States)
2022-2024
Abstract Rabies is a lethal zoonotic disease that mainly caused by the rabies virus (RABV). Although effective vaccines have long existed, current take both time and cost to produce. Messenger RNA (mRNA) technology an emergent vaccine platform supports rapid development on large scale. Here, optimized mRNA construct (LVRNA001) expressing glycoprotein (RABV-G) was developed in vitro then evaluated vivo for its immunogenicity protective capacity mice dogs. LVRNA001 induced neutralizing...
Abstract Rabies is a lethal disease caused by the rabies virus (RABV), which causes acute neurological infections in mammals, including human beings. We previously reported that an mRNA vaccine (LVRNA001) encoding virus’s glycoprotein induced strong protective immune responses to mice and dogs. Here, we further evaluate safety of LVRNA001. First, performed confirmative efficacy study dogs, showed LVRNA001 fully protected animals from virus, both pre- post-infection. Moreover, using...
Respiratory syncytial virus (RSV) causes the most common type of severe lower respiratory tract infection worldwide, and fusion (F) protein is a target for neutralizing antibodies vaccine development. This study aimed to investigate immunogenicity efficacy an mRNA-based RSV with F sequence. We designed mRNA construct encoding modified protein, which was further developed into LNP-encapsulated (LVRNA007). LVRNA007 administered mice cotton rats, followed by analysis viral challenge studies....
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected billions of individuals and is the cause current global disease 2019 (COVID-19) pandemic. We previously developed an mRNA vaccine (LVRNA009) based on S protein Wuhan-Hu-1 strain; phases I II clinical trials showed that LVRNA009 a promising safety immunogenicity profile. In order to counteract immune escape by SARS-CoV-2 variants concern, panel vaccines was proteins Wuhan-Hu-1, Delta, Omicron BA.1, BA.2, BA.5...
ABSTRACT Highly pathogenic viruses from family Phenuiviridae , which are mainly transmitted by arthropods, have intermittently sparked epidemics worldwide. In particular, tick-borne bandaviruses, such as severe fever with thrombocytopenia syndrome virus (SFTSV), continue to spread in mountainous areas, resulting an average mortality rate high 10.5%, highlighting the urgency and importance of vaccine development. Here, mRNA developed based on full-length SFTSV glycoprotein, containing both...
mRNA injection-based protein supplementation has emerged as a feasible treatment for Fabry disease. However, whether the introduction of LNP-encapsulated results in alteration metabolomics an vivo system remains largely unknown. In present study, α-galactosidase A (α-Gal A) was generated and injected into disease mouse model. The α-Gal successfully expressed. level globotriaosylsphingosine (Lyso-Gb3), biomarker disease, well pro-inflammatory cytokines such nuclear factor kappa-B (NF-κB),...